Cure8 trial brief
A dietary multi-mineral supplement is being tested in a Phase 2 trial to see if it can improve symptoms, influence inflammation biomarkers, and help induce or maintain remission in people with ulcerative colitis.
Adults with mild ulcerative colitis or UC in remission, GI clinicians, and researchers interested in dietary/supplement interventions, biomarkers, and trial-based outcomes.
The study (NCT03869905) is active but not recruiting and plans to enroll about 40 adults at the University of Michigan. Participants take 4 capsules daily (about 800 mg calcium/day) for 180 days in the Aquamin® arm; there is a crossover arm with placebo for the first 90 days then Aquamin® for the last 90 days.
Primary outcomes include patient-reported IBDQ quality-of-life score, endoscopic/clinical disease activity (Mayo/UCDAI), tissue IL-8 cytokine levels, serum CRP, and fecal calprotectin measured through day 180.
How this may affect people with IBD: This trial is testing a dietary supplement approach rather than a prescription drug; outcomes include both symptom scores and objective inflammatory biomarkers and endoscopy.
This is a registered Phase 2 interventional trial (active, not recruiting) with planned enrollment of ~40 participants at a single U.S. site. As a trial record, it describes planned interventions and outcomes but does not report results.
The supplement contains high calcium and excludes participants with kidney disease or hypercalcemia; pregnancy testing and medication restrictions are part of eligibility.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Vitamin D supplementation is commonly considered in people with IBD because deficiency is frequent and low vitamin D may relate to inflammation.
The study suggests nickel accumulation and iron deficiency may be linked with more severe IBD. If confirmed, blood metal and micronutrient levels could help researchers understand disease mechanisms and guide nutritional...
This study reports real-world data on mirikizumab in adults with ulcerative colitis, focusing on clinical and endoscopic remission and inflammatory markers — outcomes patients and clinicians use to judge treatment...
